Munich, Germany and Durham, NC – TEM International GmbH and Technology Commercialization Group, LLC (TCG) announce the successful completion of a five year assignment in which TCG managed the US market entry of the ROTEM delta hemostasis analyzer. The ROTEM delta is a diagnostic instrument designed to give clinicians the most rapid and complete information to manage bleeding patients. It is used worldwide during cardiovascular, transplant and trauma surgeries.
TCG, based in the Research Triangle Park area of North Carolina, is an international consulting firm that specializes in helping European medical device, diagnostics and biotechnology companies enter the US market. As part of this multi-year assignment, TCG established and developed TEM International’s US subsidiary, TEM Systems, Inc., then hired and managed a national sales, marketing, distribution and customer service organization. The product was cleared by the FDA in August, 2011 and was launched at that time.
“We’re pleased to have helped TEM International enter the US market with a technology that not only is saving lives, but is helping hospitals control costs by eliminating unnecessary transfusions,” commented Ken West, Managing Partner of TCG and formerly president of TEM Systems, Inc.
The ROTEM delta hemostasis analyzer system provides in-depth information on all three stages of hemostasis, which goes beyond the routine testing that is currently done during surgery. A better understanding of patients’ hemostasis means fewer unnecessary blood transfusions. The value of the ROTEM system has been demonstrated in more than 500 publications by clinical leaders, and more than 2000 systems are in use around the world.
Dr. Thomas Ebinger, CEO of TEM International, added “TCG is a unique resource. Their understanding of the US medical device market and operational expertise is a perfect fit for mid-sized companies entering the US. Working with TCG, we built our US subsidiary and have had a smooth and successful launch. With this foundation, TEM Systems and the ROTEM instrument are now expecting strong growth throughout the US market.”
After its initial operational role, TCG is continuing to assist TEM International on a number of strategic initiatives to further solidify ROTEM’s worldwide leadership position in the field of hemostasis diagnostics.
About TEM International – TEM International GmbH, based in Munich Germany, has developed and markets the ROTEM hemostasis analyzer. Used in over 2000 clinical locations worldwide, the ROTEM delta provides the most rapid and complete information on hemostasis, helping clinicians to better manage bleeding patients. More information about ROTEM and Tem International can be found at www.tem-international.de.
About TCG — TCG is a consulting company formed in 1998 and based in the Research Triangle Park region of North Carolina. TCG works closely with medical device, diagnostic, biotechnology, pharmaceutical and other life science companies to develop and implement successful commercial strategies for new products and markets. TCG consultants are all former senior executives of successful life science companies. More information about TCG can be found at www.tcgmedtech.com.
Thomas Ebinger at Tem International GmbH: firstname.lastname@example.org
Ken West at TCG, LLC: email@example.com